GWpharmaceuticals

Founded in 1998, GW Pharmaceuticals is a UK-based, biopharmaceutical company that has built a well-known presence for their contribution of prescription medical cannabis products.

Sativex is a cannabis-infused mouth spray created by GW Pharmaceuticals in the US over a decade ago. It was approved in 2010 in the UK to support patients with multiple sclerosis and severe neuropathic pain caused by cancer. It has since been approved in 25 countries outside the US. According to their website, GW Pharmaceuticals was planning on filing an NDA in the US by the end of 2019, with clinical trials expected to follow soon after.

GW Pharmaceuticals is also responsible for the creation of Epidiolex, the first FDA-approved cannabis-derived prescription medicine in the US. Epidiolex is a purified CBD oil approved for patients ages 2 and over for the treatment of two rare and intractable forms of epilepsy, Lennox-Gastaut Syndrome and Dravet Syndrome. Epidiolex was approved in the US in 2018 and recently approved in the EU under the name Epidyolex. In a 2019 presentation, GW Pharmaceuticals announced that 2,500 physicians had written over 12,000 prescriptions for the drug since its launch.

GW Pharmaceuticals has been cultivating their own cannabis plants since 1998 when the company was founded. To this day, they control all facets of product development from cultivation to commercial distribution. GW Pharmaceutical’s cannabis-derived prescription medicines are developed by a global network of cannabinoid scientists and an internal group of over 700 employees highly experienced in creating cannabinoid-based medicines and plant-based pharmaceutical-grade prescription products. All of their products are created to meet strict GMP regulations set in place by the FDA.

Aside from Sativex and Epidiolex, GW Pharmaceuticals currently has “a deep pipeline of additional clinical-stage cannabinoid products under development.”